Examen systématique du rituximab pour les maladies auto-immunes: une alternative potentielle à l’immunoglobuline en IV

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar du membre

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 5752
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
Âge : 63
    Windows 10 Firefox
Genre :
Zodiaque :
Âge : 63
Contact :
France

Examen systématique du rituximab pour les maladies auto-immunes: une alternative potentielle à l’immunoglobuline en IV

Message par Pboulanger » 15 oct. 2018 10:39

:hi:

:arrow: Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/30244480



Traduction disponible directement en cliquant en bas à droite de ce message sur l'expression Traduire en

Image

 Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin.MacIsaac J1, Siddiqi R1, Jamula E1, Li N1, Baker S1, Webert KE2, Evanovitch D3, Heddle NM1,2, Arnold DM1,2.

Transfusion. 2018 Sep 23. doi: 10.1111/trf.14841.


Abstract
  • BACKGROUND:
The anti-CD20 monoclonal antibody rituximab has immune-modulatory effects similar to intravenous immunoglobulin (IVIG). We performed a systematic review and meta-analysis to determine the efficacy and safety of rituximab in autoimmune diseases that are also treated with IVIG.
  • STUDY DESIGN AND METHODS:
The most common indications for immune modulation with IVIG, as identified from a 2012 regional audit in Canada, were chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP), myasthenia gravis, multifocal motor neuropathy, Guillain-Barré syndrome, systemic lupus erythematosus (SLE), Sjogren's syndrome, and pemphigus vulgaris. We searched MEDLINE, EMBASE, and the Cochrane Library until July 2016 for studies evaluating rituximab in each of these conditions. The primary outcome in our meta-analysis was clinical response at 6 months as defined by disease-specific criteria in randomized trials. We also calculated pooled proportions of responders within disease types from observational studies.
  • RESULTS:
Ninety-five rituximab studies were identified: 86 were observational studies in patients with ITP (n = 1746), SLE (n = 1047), pemphigus vulgaris (n = 564), Sjogren's syndrome (n = 138), myasthenia gravis (n = 66), and CIDP (n = 31) and nine were randomized controlled trials (n = 992) in patients with ITP, SLE, and Sjogren's syndrome that compared rituximab with placebo plus standard of care. Among randomized trials, response rates were higher with rituximab (relative risk, 1.38; 95% confidence interval [CI], 1.05-1.83). The pooled proportion of rituximab responses ranged from 94% (95% CI, 88%-98%) for pemphigus vulgaris to 48% (95% CI, 30%-66%) for CIDP. Rituximab was generally well tolerated in observational studies although in the randomized trials, adverse events were more common in the rituximab group.
  • CONCLUSION:
Rituximab is an immune-modulating agent with biologic activity across many autoimmune conditions. Our data support the use of comparative trials with broad eligibility criteria to evaluate rituximab as an alternative to IVIG in autoimmune diseases.    

Message d' un membre de l'équipe technique
Pour les utilisateurs d'I-phone
ci-dessous le lien vers Google Trad

https://translate.google.fr/translate?s ... t=&act=url
Message d' un membre de l'équipe technique
Nous utilisons des services automatiques de traduction fournis
par Yandex ou Google.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.
Amicalement,
Image

Répondre

Retourner vers « Informations »